Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

May 6, 2008

Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer

Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD 
Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Implications: GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.

Analysis: Good trial with an appropriate randomization. This should tell us if the agent has a future in this rather common cancer. A well spent 3 million dollars by Genentech. Chance of benefit?? At least the study is designed to answer the question.

Other Analyses of the Same Source Article:
Hedgehog pathwa drugs and chemotherapy
May 7, 2008, Author: Donald Fleming, MD, Division Head of Hematology and Oncology, MEDICAL CENTER OF VINCENNES

Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics